CELEX: 62007TA0493
Language: en
Date: 2009-09-23 00:00:00
Title: Joined Cases T-493/07, T- 26/08 and T-27/08: Judgment of the Court of First Instance of 23 September 2009 — GlaxoSmithKline and others v OHIM — Serono Genetics Institute (FAMOXIN) (Community trade mark — Invalidity proceedings — Community word mark FAMOXIN — Earlier national word marks LANOXIN — Relative ground for refusal — No likelihood of confusion — Article 8(1)(b) and Article 52(1)(a) of Regulation (EC) No 40/94 (now Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009) — Proof of use — Article 56(2) and (3) of Regulation No 40/94 (now Article 57(2) and (3) of Regulation No 207/2009)

7.11.2009   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 267/62
            
         Judgment of the Court of First Instance of 23 September 2009 — GlaxoSmithKline and others v OHIM — Serono Genetics Institute (FAMOXIN)
   (Joined Cases T-493/07, T- 26/08 and T-27/08) (1)
   
   (Community trade mark - Invalidity proceedings - Community word mark FAMOXIN - Earlier national word marks LANOXIN - Relative ground for refusal - No likelihood of confusion - Article 8(1)(b) and Article 52(1)(a) of Regulation (EC) No 40/94 (now Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009) - Proof of use - Article 56(2) and (3) of Regulation No 40/94 (now Article 57(2) and (3) of Regulation No 207/2009)
   2009/C 267/109
   Language of the case: English
   
      Parties
   
   
      Applicants: GlaxoSmithKline SpA (Verona, Italy); Laboratórios Wellcome de Portugal Lda (Algés, Portugal); and The Wellcome Foundation Ltd (Greenford, Middlesex, United Kingdom) (represented by: R. Gilbey, Lawyer)
   
      Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: A. Folliard-Monguiral and D. Botis, Agents)
   
      Other party to the proceedings before the Board of Appeal of OHIM intervening before the Court of First Instance: Serono Genetics Institute SA, (Évry, France)
   
      Re:
   
   Three actions brought against the decisions of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 14 September 2007 (Case R 8/2007-1), 20 November 2007 (Case R 10/2007-1) and 19 November 2007 (Case R 9/2007-1), relating to cancellation proceedings between, on the one hand, GlaxoSmithkline SpA, Laboratórios Wellcome De Portugal Lda and The Wellcome Foundation Ltd, and, on the other, Serono Genetics Institute SA.
   
      Operative part of the judgment
   
   The Court:
   
               1.
            
            
               Joins Cases T-493/07, T-26/08 and T-27/08 for the purposes of the present judgment;
            
         
               2.
            
            
               Dismisses the actions;
            
         
               3.
            
            
               Orders GlaxoSmithKline SpA, Laboratórios Wellcome de Portugal, Lda and The Wellcome Foundation Ltd to pay the costs.
            
         
      (1)  OJ C 51, 23.2.2008.